Login to Your Account

Shenogen nabs China rights to Angiochem's paclitaxel-peptide drug conjugate

By Shannon Ellis
Staff Writer

Thursday, January 4, 2018

SHANGHAI – Xinogen (Hong Kong) Pharma Co. Ltd., a subsidiary of Beijing Shenogen Pharmaceuticals Group, has negotiated a deal with Angiochem Inc., of Montreal, to develop and sell ANG-1005, a paclitaxel-peptide drug conjugate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription